SCHEMBL8293133

SCHEMBL8293133

Cc1cc(C)cc(NCc2ccc3nc(NCC4COC(C)(C)O4)n(Cc4nc(C)ccc4O)c3c2)c1

nearest known ligand 0.35

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 13/20 0.35
LMNA P02545 2/20 0.33
TRPC5 Q9UL62 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
HTT P42858 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8294772 0.89 P2RX3 (0.36) P2RX3LMNATRPC5SMN1; SMN2HTT
SCHEMBL8293134 0.83 P2RX3 (0.34) P2RX3TRPC5
SCHEMBL12852013 0.83 TRPC5 (0.43) P2RX3TRPC5
SCHEMBL4278120 0.81 P2RX3 (0.33) P2RX3TRPC5
SCHEMBL8294773 0.80 IDH1 (0.36) P2RX3TRPC5SMN1; SMN2
SCHEMBL1238181 0.78 LMNA (0.37) LMNASMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL4853794 0.77 MCHR1 (0.36) LMNATRPC5SMN1; SMN2CYP1A2CYP3A4
SCHEMBL14002705 0.77 MCHR1 (0.36) LMNATRPC5SMN1; SMN2CYP1A2CYP3A4
SCHEMBL4864355 0.76 TRPC5 (0.44) LMNATRPC5
SCHEMBL1238344 0.76 MCHR1 (0.39) LMNATRPC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278455-B2 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-02 US disclosed
US-8278455-B2 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-02 US disclosed
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION JANSSEN SCIENCES IRELAND UC (IE) 2009-03-05 US disclosed
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION JANSSEN SCIENCES IRELAND UC (IE) 2009-03-05 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed
WO-2005058874-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 P2RX3 1849/4885LMNA 1049/4885TRPC5 2236/4885
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 P2RX3 1861/4885LMNA 766/4885TRPC5 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.